Gen­mab en­lists an­oth­er an­ti­body con­ju­gate part­ner, team­ing up with Bolt to de­vel­op up to 3 can­cer pro­grams

Big Dan­ish biotech Gen­mab has signed on to a new col­lab­o­ra­tion, and it’s one both par­ties hope will tack­le a broad swath of can­cer in­di­ca­tions.

Gen­mab is part­ner­ing with Bolt Bio­ther­a­peu­tics out of Red­wood City, CA, to de­vel­op up to three new an­ti­body-based con­ju­gates in on­col­o­gy. In the deal, Gen­mab is pay­ing Bolt $10 mil­lion up­front and in­vest­ing $15 mil­lion in eq­ui­ty, and Bolt is el­i­gi­ble for up to $285 mil­lion in mile­stones per tar­get — a to­tal that could equal $855 mil­lion when all is said and done.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER